Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
NCT02572843
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
68
Enrollment
OTHER
Sponsor class
Conditions
NSCLC Non-small Cell Lung Cancer
Interventions
DRUG:
MEDI4736 (anti-PD-L1)
Sponsor
Swiss Cancer Institute